Patent 10434175 was granted and assigned to Compass Therapeutics Llc on October, 2019 by the United States Patent and Trademark Office.
The present disclosure relates to compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.